Episode 6 – Lessons learned part one: the value of biosimilars in oncology
01 września 2025
In Episode 6 of the Illuminoz podcast series, Bianca Stadler speaks with Professor Kai Hübel – hematologist and oncologist from the University Hospital of Cologne – about the oncology community’s experience with biosimilars and what it can teach us about their role in multiple sclerosis.
How did biosimilars become standard of care in cancer treatment? What benefits have they brought in terms of access, affordability, and sustainability? And how can these lessons be applied to MS?
Tune in for a cross-disciplinary perspective on how biosimilars can transform care beyond oncology.
Informacje o podcaście:
“Illuminoz talks 2025” podcast series:
Episode 12 – PML: what is it, and why is it relevant in MS?
dr Tobias Bopp,
Episode 11 – Introducing biosimilar natalizumab
dr Heinz Wiendl,
Episode 10 – Patient conversations part three: the patient perspective
Ellen Tutton,
Episode 9 – Patient conversations part two: the nurse perspective
karolinamalicka,
Episode 8 – Patient conversations part one: the neurologist perspective
dr Agne Straukiene,
Episode 7 – Lessons learned part two: the value of biosimilars in rheumatology
prof. Paul Emery,
Episode 5 – Biosimilars and MS: improving access to high-efficacy treatment
dr Barbara Kornek,
Episode 4 – Treatment paradigms in MS: right patient, right treatment, right time
dr Laura Airas,
Episode 3 – MS treatment landscape part two: potential role of biosimilars
dr David Paling,
Episode 2 – MS treatment landscape part one: unmet needs
dr Luisa Klotz,
Episode 1 – Biosimilars: what are they, and why might they be important for MS?
dr Wallace Brownlee,
